Thomas A. Perry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas A. Perry has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Nigel K. Arden
Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
13 shared publications - David T. Felson
Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
7 shared publications - David John Hunter
Faculty of Medicine and Health, Sydney Musculoskeletal Health, Kolling Institute, The University of Sydney, Sydney, Australia
6 shared publications - Lucy Gates
Institute for Life Sciences, University of Southampton, UK
6 shared publications - Cyrus Cooper
MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton SO16 6YD, UK
5 shared publications - Tonia L. Vincent
Centre for OA Pathogenesis, Kennedy Institute of Rheumatology, University of Oxford
5 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum
Knee osteoarthritis affects 40% of people during their lifetime, significantly impacting societies worldwide. Its molecular pathogenesis remains poorly understood and variable clinical phenotypes suggest it may be more than one disease. We established S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) to search for molecular endotypes in knee OA synovial fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype-enriched targetable pathways, and a rationale for stratification in clinical trial design.
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessLarge-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum
Knee osteoarthritis affects 40% of people during their lifetime, significantly impacting societies worldwide. Its molecular pathogenesis remains poorly understood and variable clinical phenotypes suggest it may be more than one disease. We established S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) to search for molecular endotypes in knee OA synovial fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype-enriched targetable pathways, and a rationale for stratification in clinical trial design.
- Open Access
- 22 September 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (9) , e70085
Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression
Objective: The Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify, develop, and qualify biomarkers to support drug development in knee osteoarthritis (OA). The project's second phase, the PROGRESS OA study, aims to externally validate prognostic and response biomarkers identified in the earlier phase (phase 1). Here we present results assessing external validation of prognostic imaging biomarkers.Design: PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for symptomatic knee OA. Radiographic progression was defined as joint space width loss (JSWL) ≥0.7 mm. Symptomatic progression was defined as increase of nine or more points in Western Ontario and McMaster Universities Arthritis Index pain (0–100 scale). Imaging biomarkers included quantitative measures of cartilage thickness and semiquantitative (SQ) assessments. Associations between baseline biomarkers and outcomes over 12 to 36 months were examined using logistic regression.Results: A total of 320 participants from four RCTs were included. Forty‐one participants (13%) had JSWL ≥0.7 mm and 64 (20%) had worsening symptoms. In univariable logistic regression, measures of quantitative and SQ cartilage, SQ Hoffa‐synovitis, effusion‐synovitis, and meniscal extrusion were consistently selected to predict JSWL ≥0.7 mm, similar to phase 1. SQ Hoffa‐synovitis and lateral meniscal damage were consistently selected to predict symptomatic progression. Cross‐validated areas under the curve were 0.69 (95% confidence interval [CI]: 0.53–0.85) for JSWL ≥0.7 mm and 0.77 (95% CI: 0.65–0.87) for symptomatic progression.Conclusion: The selected prognostic imaging biomarkers are candidates for enriching OA trials for structural and/or symptomatic progressors. Ongoing work includes pursuit of formal biomarker qualification by regulatory agencies, and the use of these biomarkers to capture structural progression with high sensitivity to change.
- 22 September 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (9) , e70085
Open AccessMagnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression
Objective: The Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify, develop, and qualify biomarkers to support drug development in knee osteoarthritis (OA). The project's second phase, the PROGRESS OA study, aims to externally validate prognostic and response biomarkers identified in the earlier phase (phase 1). Here we present results assessing external validation of prognostic imaging biomarkers.Design: PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for symptomatic knee OA. Radiographic progression was defined as joint space width loss (JSWL) ≥0.7 mm. Symptomatic progression was defined as increase of nine or more points in Western Ontario and McMaster Universities Arthritis Index pain (0–100 scale). Imaging biomarkers included quantitative measures of cartilage thickness and semiquantitative (SQ) assessments. Associations between baseline biomarkers and outcomes over 12 to 36 months were examined using logistic regression.Results: A total of 320 participants from four RCTs were included. Forty‐one participants (13%) had JSWL ≥0.7 mm and 64 (20%) had worsening symptoms. In univariable logistic regression, measures of quantitative and SQ cartilage, SQ Hoffa‐synovitis, effusion‐synovitis, and meniscal extrusion were consistently selected to predict JSWL ≥0.7 mm, similar to phase 1. SQ Hoffa‐synovitis and lateral meniscal damage were consistently selected to predict symptomatic progression. Cross‐validated areas under the curve were 0.69 (95% confidence interval [CI]: 0.53–0.85) for JSWL ≥0.7 mm and 0.77 (95% CI: 0.65–0.87) for symptomatic progression.Conclusion: The selected prognostic imaging biomarkers are candidates for enriching OA trials for structural and/or symptomatic progressors. Ongoing work includes pursuit of formal biomarker qualification by regulatory agencies, and the use of these biomarkers to capture structural progression with high sensitivity to change.
- Open Access
- 5 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (4) , 100677
Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study
- 5 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (4) , 100677
Open AccessBiochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study
- Top Cited Papers
- 12 August 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (9) , 526-545
Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain
Pain is the primary complaint in individuals with osteoarthritis (OA) and changes as the disease progresses. Anatomical changes in several joint structures potentially contribute to pain, including the increased innervation of the periosteum, synovium and subchondral bone, and the pathological innervation of articular cartilage, which is aneural under physiological conditions. Research has focused on molecules that sensitize afferent neurons, such as neuropeptides, neurotrophins, pro-inflammatory cytokines and ion channels. The neurotrophin nerve growth factor (NGF) is the best validated target in OA pain, with proven analgesic effects in preclinical and clinical studies, although the development of NGF-targeted therapeutics has been hampered by serious side effects. One relatively neglected area of research is the contribution to OA pain of the molecular pathways that mediate remodelling of nerves in disease. Remodelling requires coordination between the nerve and the associated vasculature, along with signals that are received from the surrounding parenchyma. Key cell guidance molecules, including angiogenic factors, ephrins, semaphorins and SLIT proteins are involved in nerve growth during development, and their expression is increased in osteoarthritic joints.
- 12 August 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (9) , 526-545
Top Cited PapersPeripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain
Pain is the primary complaint in individuals with osteoarthritis (OA) and changes as the disease progresses. Anatomical changes in several joint structures potentially contribute to pain, including the increased innervation of the periosteum, synovium and subchondral bone, and the pathological innervation of articular cartilage, which is aneural under physiological conditions. Research has focused on molecules that sensitize afferent neurons, such as neuropeptides, neurotrophins, pro-inflammatory cytokines and ion channels. The neurotrophin nerve growth factor (NGF) is the best validated target in OA pain, with proven analgesic effects in preclinical and clinical studies, although the development of NGF-targeted therapeutics has been hampered by serious side effects. One relatively neglected area of research is the contribution to OA pain of the molecular pathways that mediate remodelling of nerves in disease. Remodelling requires coordination between the nerve and the associated vasculature, along with signals that are received from the surrounding parenchyma. Key cell guidance molecules, including angiogenic factors, ephrins, semaphorins and SLIT proteins are involved in nerve growth during development, and their expression is increased in osteoarthritic joints.
- Open Access
- 18 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0309677
Development of methodology to support molecular endotype discovery from synovial fluid of individuals with knee osteoarthritis: The STEpUP OA consortium
Objectives: To develop a protocol for largescale analysis of synovial fluid proteins, for the identification of biological networks associated with subtypes of osteoarthritis. Methods: Synovial Fluid To detect molecular Endotypes by Unbiased Proteomics in Osteoarthritis (STEpUP OA) is an international consortium utilising clinical data (capturing pain, radiographic severity and demographic features) and knee synovial fluid from 17 participating cohorts. 1746 samples from 1650 individuals comprising OA, joint injury, healthy and inflammatory arthritis controls, divided into discovery (n = 1045) and replication (n = 701) datasets, were analysed by SomaScan Discovery Plex V4.1 (>7000 SOMAmers/proteins). An optimised approach to standardisation was developed. Technical confounders and batch-effects were identified and adjusted for. Poorly performing SOMAmers and samples were excluded. Variance in the data was determined by principal component (PC) analysis. Results: A synovial fluid standardised protocol was optimised that had good reliability (80% of SOMAmers in pooled samples) and overall good correlation with immunoassay. 1720 samples and >6290 SOMAmers met inclusion criteria. 48% of data variance (PC1) was strongly correlated with individual SOMAmer signal intensities, particularly with low abundance proteins (median correlation coefficient 0.70), and was enriched for nuclear and non-secreted proteins. We concluded that this component was predominantly intracellular proteins, and could be adjusted for using an ‘intracellular protein score’ (IPS). PC2 (7% variance) was attributable to processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other technical confounders. Data visualisation revealed clustering of injury and OA cases in overlapping but distinguishable areas of high-dimensional proteomic space. Conclusions: We have developed a robust method for analysing synovial fluid protein, creating a molecular and clinical dataset of unprecedented scale to explore potential patient subtypes and the molecular pathogenesis of OA. Such methodology underpins the development of new approaches to tackle this disease which remains a huge societal challenge.
- 18 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0309677
Open AccessDevelopment of methodology to support molecular endotype discovery from synovial fluid of individuals with knee osteoarthritis: The STEpUP OA consortium
Objectives: To develop a protocol for largescale analysis of synovial fluid proteins, for the identification of biological networks associated with subtypes of osteoarthritis. Methods: Synovial Fluid To detect molecular Endotypes by Unbiased Proteomics in Osteoarthritis (STEpUP OA) is an international consortium utilising clinical data (capturing pain, radiographic severity and demographic features) and knee synovial fluid from 17 participating cohorts. 1746 samples from 1650 individuals comprising OA, joint injury, healthy and inflammatory arthritis controls, divided into discovery (n = 1045) and replication (n = 701) datasets, were analysed by SomaScan Discovery Plex V4.1 (>7000 SOMAmers/proteins). An optimised approach to standardisation was developed. Technical confounders and batch-effects were identified and adjusted for. Poorly performing SOMAmers and samples were excluded. Variance in the data was determined by principal component (PC) analysis. Results: A synovial fluid standardised protocol was optimised that had good reliability (80% of SOMAmers in pooled samples) and overall good correlation with immunoassay. 1720 samples and >6290 SOMAmers met inclusion criteria. 48% of data variance (PC1) was strongly correlated with individual SOMAmer signal intensities, particularly with low abundance proteins (median correlation coefficient 0.70), and was enriched for nuclear and non-secreted proteins. We concluded that this component was predominantly intracellular proteins, and could be adjusted for using an ‘intracellular protein score’ (IPS). PC2 (7% variance) was attributable to processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other technical confounders. Data visualisation revealed clustering of injury and OA cases in overlapping but distinguishable areas of high-dimensional proteomic space. Conclusions: We have developed a robust method for analysing synovial fluid protein, creating a molecular and clinical dataset of unprecedented scale to explore potential patient subtypes and the molecular pathogenesis of OA. Such methodology underpins the development of new approaches to tackle this disease which remains a huge societal challenge.
- Open Access
Deconvoluting synovial fluid molecular endotypes in knee osteoarthritis: primary results from the STEpUP OA Consortium
Background: Osteoarthritis (OA) has a lifetime risk of over 40%, imposing a huge societal burden. Clinical variability suggests that it could be more than one disease. S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) was established to test the hypothesis that there are detectable distinct molecular endotypes in knee OA. Methods: OA knee synovial fluid (SF) samples (N=1361) were from pre-existing OA cohorts with cross-sectional clinical (radiographic and pain) data. Samples were divided into Discovery (N = 708) and Replication (N=653) datasets. Proteomic analysis was performed using SomaScan V4.1 assay (6596 proteins). Unsupervised clustering was performed using k-means, assessed using the f(k) metric, with and without adjustments for potential confounders. Regression analyses were used to assess protein associations with radiographic (Kellgren and Lawrence) and knee pain (WOMAC pain), with and without stratification by body mass index (BMI) or biological sex. Adjustments were made for cohort (random intercept) or intracellular protein, using an intracellular protein score (IPS). Analyses were carried out in R according to a pre-published plan. Results: No distinct SF molecular endotypes were identified in OA but two indistinct clusters were defined in non-IPS regressed data which were stable across subgroup analyses. Clustering was lost after IPS regression adjustment. Strong, replicable protein associations were observed with radiographic disease severity, which were retained after adjustment for cohort or IPS. Pathway analysis identified a strong “epithelial to mesenchymal transition (EMT)” pathway, and weaker associations with “angiogenesis”, “complement” and “coagulation”. The latter were variably lost after adjustment for BMI or biological sex. Associations with patient reported pain were weaker. Conclusion: These data support knee OA as a biologically continuous disease in which disease severity is associated with a strong, robust, tissue remodelling signature. Subtle differences were found in pathways after stratification by BMI or sex.
Open AccessDeconvoluting synovial fluid molecular endotypes in knee osteoarthritis: primary results from the STEpUP OA Consortium
Background: Osteoarthritis (OA) has a lifetime risk of over 40%, imposing a huge societal burden. Clinical variability suggests that it could be more than one disease. S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) was established to test the hypothesis that there are detectable distinct molecular endotypes in knee OA. Methods: OA knee synovial fluid (SF) samples (N=1361) were from pre-existing OA cohorts with cross-sectional clinical (radiographic and pain) data. Samples were divided into Discovery (N = 708) and Replication (N=653) datasets. Proteomic analysis was performed using SomaScan V4.1 assay (6596 proteins). Unsupervised clustering was performed using k-means, assessed using the f(k) metric, with and without adjustments for potential confounders. Regression analyses were used to assess protein associations with radiographic (Kellgren and Lawrence) and knee pain (WOMAC pain), with and without stratification by body mass index (BMI) or biological sex. Adjustments were made for cohort (random intercept) or intracellular protein, using an intracellular protein score (IPS). Analyses were carried out in R according to a pre-published plan. Results: No distinct SF molecular endotypes were identified in OA but two indistinct clusters were defined in non-IPS regressed data which were stable across subgroup analyses. Clustering was lost after IPS regression adjustment. Strong, replicable protein associations were observed with radiographic disease severity, which were retained after adjustment for cohort or IPS. Pathway analysis identified a strong “epithelial to mesenchymal transition (EMT)” pathway, and weaker associations with “angiogenesis”, “complement” and “coagulation”. The latter were variably lost after adjustment for BMI or biological sex. Associations with patient reported pain were weaker. Conclusion: These data support knee OA as a biologically continuous disease in which disease severity is associated with a strong, robust, tissue remodelling signature. Subtle differences were found in pathways after stratification by BMI or sex.
- Open Access
Methodological development of molecular endotype discovery from synovial fluid of individuals with knee osteoarthritis: the STEpUP OA Consortium
Objectives To develop and validate a pipeline for quality controlled (QC) protein data for largescale analysis of synovial fluid (SF), using SomaLogic technology. Design Knee SF and associated clinical data were from partner cohorts. SF samples were centrifuged, supernatants stored at −80 °C, then analysed by SomaScan Discovery Plex V4.1 (>7000 SOMAmers/proteins). Setting An international consortium of 9 academic and 8 commercial partners (STEpUP OA). Participants 1746 SF samples from 1650 individuals comprising OA, joint injury, healthy controls and inflammatory arthritis controls, divided into discovery (n=1045) and replication (n=701) datasets. Primary and secondary outcome measures An optimised approach to standardisation was developed iteratively, monitoring reliability and precision (comparing coefficient of variation [%CV] of ‘pooled’ SF samples between plates and correlation with prior immunoassay for 9 analytes). Pre-defined technical confounders were adjusted for (by Limma) and batch correction was by ComBat. Poorly performing SOMAmers and samples were filtered. Variance in the data was determined by principal component (PC) analysis. Data were visualised by Uniform Manifold Approximation and Projection (UMAP). Results Optimal SF standardisation aligned with that used for plasma, but without median normalisation. There was good reliability (80% of SOMAmers in pooled samples) and overall good correlation with immunoassay. PC1 accounted for 48% of variance and strongly correlated with individual SOMAmer signal intensities (median correlation coefficient 0.70). These could be adjusted using an ‘intracellular protein score’. PC2 (7% variance) was attributable to processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other technical confounders. Data visualisation by UMAP revealed clustering of injury and OA cases in overlapping but distinguishable areas of high-dimensional proteomic space. Conclusions We define a standardised approach for SF analysis using the SOMAscan platform and identify likely ‘intracellular’ protein as being a major driver of variance in the data. Strengths and limitations This is the largest number of individual synovial fluid samples analysed by a high content proteomic platform (SomaLogic technology) SomaScan offers reliable, precise relative SF data following standardisation for over 6000 proteins Significant variance in the data was driven by a protein signal which is likely intracellular in origin: it is not yet clear whether this is due to technical considerations, normal cell turnover or relevant pathological processes Adjusting for confounding factors might conceal the true structure of the data and reduce the ability to detect ‘molecular endotypes’ within disease groups
Open AccessMethodological development of molecular endotype discovery from synovial fluid of individuals with knee osteoarthritis: the STEpUP OA Consortium
Objectives To develop and validate a pipeline for quality controlled (QC) protein data for largescale analysis of synovial fluid (SF), using SomaLogic technology. Design Knee SF and associated clinical data were from partner cohorts. SF samples were centrifuged, supernatants stored at −80 °C, then analysed by SomaScan Discovery Plex V4.1 (>7000 SOMAmers/proteins). Setting An international consortium of 9 academic and 8 commercial partners (STEpUP OA). Participants 1746 SF samples from 1650 individuals comprising OA, joint injury, healthy controls and inflammatory arthritis controls, divided into discovery (n=1045) and replication (n=701) datasets. Primary and secondary outcome measures An optimised approach to standardisation was developed iteratively, monitoring reliability and precision (comparing coefficient of variation [%CV] of ‘pooled’ SF samples between plates and correlation with prior immunoassay for 9 analytes). Pre-defined technical confounders were adjusted for (by Limma) and batch correction was by ComBat. Poorly performing SOMAmers and samples were filtered. Variance in the data was determined by principal component (PC) analysis. Data were visualised by Uniform Manifold Approximation and Projection (UMAP). Results Optimal SF standardisation aligned with that used for plasma, but without median normalisation. There was good reliability (80% of SOMAmers in pooled samples) and overall good correlation with immunoassay. PC1 accounted for 48% of variance and strongly correlated with individual SOMAmer signal intensities (median correlation coefficient 0.70). These could be adjusted using an ‘intracellular protein score’. PC2 (7% variance) was attributable to processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other technical confounders. Data visualisation by UMAP revealed clustering of injury and OA cases in overlapping but distinguishable areas of high-dimensional proteomic space. Conclusions We define a standardised approach for SF analysis using the SOMAscan platform and identify likely ‘intracellular’ protein as being a major driver of variance in the data. Strengths and limitations This is the largest number of individual synovial fluid samples analysed by a high content proteomic platform (SomaLogic technology) SomaScan offers reliable, precise relative SF data following standardisation for over 6000 proteins Significant variance in the data was driven by a protein signal which is likely intracellular in origin: it is not yet clear whether this is due to technical considerations, normal cell turnover or relevant pathological processes Adjusting for confounding factors might conceal the true structure of the data and reduce the ability to detect ‘molecular endotypes’ within disease groups
- Open Access
- 15 May 2022
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 4 (3) , 100272
An open-label, single-arm trial of cryoneurolysis for improvements in pain, activities of daily living and quality of life in patients with symptomatic ankle osteoarthritis
- 15 May 2022
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 4 (3) , 100272
Open AccessAn open-label, single-arm trial of cryoneurolysis for improvements in pain, activities of daily living and quality of life in patients with symptomatic ankle osteoarthritis
- Open Access
- 7 May 2022
- Published by Wiley in Journal of Foot and Ankle Research
- Vol. 15 (1) , 1-7
Survival of primary ankle replacements: data from global joint registries
Background: Ankle arthroplasty, commonly known as ankle replacement, is a surgical procedure for treating end‐stage ankle osteoarthritis. Whilst evidence shows good clinical results after surgery, little is known of the long‐term survival of ankle replacements and the need for ankle revision. Using more recent implant data and long‐term data, there is now opportunity to examine at a population‐level the survival rate for ankle implants, to examine between‐country differences in ankle revision surgery, and to compare temporal trends in revision rates between countries.Methods: Four national joint registries from Australia, New Zealand, Norway and Sweden provided the necessary data on revision outcome following primary ankle replacement, for various periods of observation – the earliest starting in 1993 up to the end of 2019. Data were either acquired from published, online annual reports or were provided from direct contact with the joint registries. The key information extracted were Kaplan‐Meier estimates to plot survival probability curves following primary ankle replacement.Results: The survival rates varied between countries. At 2 years, across all registries, survival rates all exceeded 0.9 (range 0.91 to 0.97). The variation widened at 5 years (range 0.80 to 0.91), at 10 years (range 0.66 to 0.84) and further at 15‐years follow‐up (0.56 to 0.78). At each time point, implant survival was greater in Australia and New Zealand with lower rates in Sweden and Norway.Conclusions: We observed variation in primary ankle replacement survival rates across these national registries, although even after 5 years, these population derived data show an 80% revision free survival. These data raise a number of hypotheses concerning the reasons for between‐country differences in revision‐free survival which will require access to primary data for analysis.
- 7 May 2022
- Published by Wiley in Journal of Foot and Ankle Research
- Vol. 15 (1) , 1-7
Open AccessSurvival of primary ankle replacements: data from global joint registries
Background: Ankle arthroplasty, commonly known as ankle replacement, is a surgical procedure for treating end‐stage ankle osteoarthritis. Whilst evidence shows good clinical results after surgery, little is known of the long‐term survival of ankle replacements and the need for ankle revision. Using more recent implant data and long‐term data, there is now opportunity to examine at a population‐level the survival rate for ankle implants, to examine between‐country differences in ankle revision surgery, and to compare temporal trends in revision rates between countries.Methods: Four national joint registries from Australia, New Zealand, Norway and Sweden provided the necessary data on revision outcome following primary ankle replacement, for various periods of observation – the earliest starting in 1993 up to the end of 2019. Data were either acquired from published, online annual reports or were provided from direct contact with the joint registries. The key information extracted were Kaplan‐Meier estimates to plot survival probability curves following primary ankle replacement.Results: The survival rates varied between countries. At 2 years, across all registries, survival rates all exceeded 0.9 (range 0.91 to 0.97). The variation widened at 5 years (range 0.80 to 0.91), at 10 years (range 0.66 to 0.84) and further at 15‐years follow‐up (0.56 to 0.78). At each time point, implant survival was greater in Australia and New Zealand with lower rates in Sweden and Norway.Conclusions: We observed variation in primary ankle replacement survival rates across these national registries, although even after 5 years, these population derived data show an 80% revision free survival. These data raise a number of hypotheses concerning the reasons for between‐country differences in revision‐free survival which will require access to primary data for analysis.
- Open Access
- 10 March 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (4) , 612-622
Recreational Physical Activity and Risk of Incident Knee Osteoarthritis: An International Meta‐Analysis of Individual Participant–Level Data
Objective: The effect of physical activity on the risk of developing knee osteoarthritis (OA) is unclear. We undertook this study to examine the relationship between recreational physical activity and incident knee OA outcomes using comparable physical activity and OA definitions.Methods: Data were acquired from 6 global, community‐based cohorts of participants with and those without knee OA. Eligible participants had no evidence of knee OA or rheumatoid arthritis at baseline. Participants were followed up for 5–12 years for incident outcomes including the following: 1) radiographic knee OA (Kellgren‐Lawrence [K/L] grade ≥2), 2) painful radiographic knee OA (radiographic OA with knee pain), and 3) OA‐related knee pain. Self‐reported recreational physical activity included sports and walking/cycling activities and was quantified at baseline as metabolic equivalents of task (METs) in days per week. Risk ratios (RRs) were calculated and pooled using individual participant data meta‐analysis. Secondary analysis assessed the association between physical activity, defined as time (hours per week) spent in recreational physical activity and incident knee OA outcomes.Results: Based on a total of 5,065 participants, pooled RR estimates for the association of MET days per week with painful radiographic OA (RR 1.02 [95% confidence interval (95% CI) 0.93–1.12]), radiographic OA (RR 1.00 [95% CI 0.94–1.07]), and OA‐related knee pain (RR 1.00 [95% CI 0.96–1.04]) were not significant. Similarly, the analysis of hours per week spent in physical activity also showed no significant associations with all outcomes.Conclusion: Our findings suggest that whole‐body, physiologic energy expenditure during recreational activities and time spent in physical activity were not associated with incident knee OA outcomes.
- 10 March 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (4) , 612-622
Open AccessRecreational Physical Activity and Risk of Incident Knee Osteoarthritis: An International Meta‐Analysis of Individual Participant–Level Data
Objective: The effect of physical activity on the risk of developing knee osteoarthritis (OA) is unclear. We undertook this study to examine the relationship between recreational physical activity and incident knee OA outcomes using comparable physical activity and OA definitions.Methods: Data were acquired from 6 global, community‐based cohorts of participants with and those without knee OA. Eligible participants had no evidence of knee OA or rheumatoid arthritis at baseline. Participants were followed up for 5–12 years for incident outcomes including the following: 1) radiographic knee OA (Kellgren‐Lawrence [K/L] grade ≥2), 2) painful radiographic knee OA (radiographic OA with knee pain), and 3) OA‐related knee pain. Self‐reported recreational physical activity included sports and walking/cycling activities and was quantified at baseline as metabolic equivalents of task (METs) in days per week. Risk ratios (RRs) were calculated and pooled using individual participant data meta‐analysis. Secondary analysis assessed the association between physical activity, defined as time (hours per week) spent in recreational physical activity and incident knee OA outcomes.Results: Based on a total of 5,065 participants, pooled RR estimates for the association of MET days per week with painful radiographic OA (RR 1.02 [95% confidence interval (95% CI) 0.93–1.12]), radiographic OA (RR 1.00 [95% CI 0.94–1.07]), and OA‐related knee pain (RR 1.00 [95% CI 0.96–1.04]) were not significant. Similarly, the analysis of hours per week spent in physical activity also showed no significant associations with all outcomes.Conclusion: Our findings suggest that whole‐body, physiologic energy expenditure during recreational activities and time spent in physical activity were not associated with incident knee OA outcomes.